Novo Nordisk A/S (NVO) Projected to Post Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) will likely be releasing its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.90 per share and revenue of $11.9651 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. On average, analysts expect Novo Nordisk A/S to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $59.40 on Monday. The firm’s fifty day simple moving average is $53.44 and its 200 day simple moving average is $54.32. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The firm has a market capitalization of $265.23 billion, a price-to-earnings ratio of 17.27 and a beta of 0.67.

Analyst Upgrades and Downgrades

Several research firms have commented on NVO. Citigroup began coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Jefferies Financial Group began coverage on Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating on the stock. BMO Capital Markets set a $57.00 price target on Novo Nordisk A/S in a research report on Monday, January 26th. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $57.79.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Very strong launch demand for Wegovy pill: IQVIA data show the pill tracked over 26,000 U.S. prescriptions in its second full week, signaling rapid uptake that supports revenue upside and market share gains in the obesity market. Novo’s Wegovy pill tracks over 26,000 prescriptions
• Positive Sentiment: Early sales momentum reinforced by reporting of ~18,000 U.S. prescriptions in week one and commentary that demand is “strong out of the gate,” which supports upside to near‑term sales and investor sentiment. Demand for Novo Nordisk’s Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
• Neutral Sentiment: Analyst view is mixed — one upgrade highlights first‑mover advantage, strong cash and aggressive U.S. marketing but also flags high valuation and potential for near‑term profit‑taking, leading to a cautious “Hold” posture. Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
• Neutral Sentiment: Public profile of Novo’s weight‑loss boom is increasing (e.g., a new Danish theatre piece), which is PR‑positive but not directly material to near‑term financials. New play in Denmark charts Novo Nordisk’s weight loss boom
• Negative Sentiment: Leadership change in China: Senior VP and head of China Christine Zhou will step down at end‑of‑March — a potential disruption given China’s importance for growth and ongoing market expansion. Novo Nordisk’s China President Zhou to step down in March
• Negative Sentiment: Near‑term headwinds flagged: analysts warn of slowing Wegovy/Ozempic momentum, pricing pressure and stronger competition that could limit upside to sales growth and margins into the Q4 earnings release. Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Johnson Financial Group Inc. boosted its stake in shares of Novo Nordisk A/S by 128.0% during the 3rd quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock valued at $38,000 after buying an additional 384 shares during the last quarter. State of Wyoming increased its stake in shares of Novo Nordisk A/S by 72.7% in the second quarter. State of Wyoming now owns 950 shares of the company’s stock worth $66,000 after buying an additional 400 shares during the last quarter. Binnacle Investments Inc raised its holdings in Novo Nordisk A/S by 126.2% in the second quarter. Binnacle Investments Inc now owns 1,190 shares of the company’s stock valued at $82,000 after acquiring an additional 664 shares in the last quarter. Palisade Asset Management LLC bought a new position in Novo Nordisk A/S during the 3rd quarter valued at $110,000. Finally, Newbridge Financial Services Group Inc. boosted its stake in Novo Nordisk A/S by 717.9% during the 3rd quarter. Newbridge Financial Services Group Inc. now owns 2,102 shares of the company’s stock valued at $117,000 after acquiring an additional 1,845 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.